Novartis AG, of Basel, Switzerland, presented results at the European Congress of Endocrinology in Wroclaw, Poland, from a pivotal phase III study of Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. Study findings showed that patients taking pasireotide long-acting release achieved greater disease control when compared to continued treatment with the standard somatostatin analogue therapies, octreotide LAR or lanreotide Autogel.